Recursion and Exscientia Shareholders Approve the Proposed Combination
13 nov. 2024 09h08 HE
|
Recursion Pharmaceuticals
Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received overwhelming approval from their shareholders for the...
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
06 nov. 2024 16h15 HE
|
Recursion Pharmaceuticals
Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and...
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
30 oct. 2024 08h22 HE
|
Recursion Pharmaceuticals
Salt Lake City, UT, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will...
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
08 août 2024 14h41 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional...
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
08 août 2024 07h30 HE
|
Recursion Pharmaceuticals
Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilitiesRecursion...
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
08 août 2024 01h32 HE
|
Recursion Pharmaceuticals
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates...
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
05 août 2024 16h01 HE
|
Recursion Pharmaceuticals
Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
26 juin 2024 22h07 HE
|
Recursion Pharmaceuticals
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
Recursion Announces Proposed Offering of Class A Common Stock
26 juin 2024 16h06 HE
|
Recursion Pharmaceuticals
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
Recursion to Participate in Upcoming Investor Conferences
03 juin 2024 09h00 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...